SCHEMBL21592277

SCHEMBL21592277

CN1CCN(c2cc3occ(CN(CCCc4cccnc4)Cc4ccncc4)c(=O)c3cc2F)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNA5 P22460 11/20 0.39
▸ KCNJ5 P48544 7/20 0.39
▸ KCNJ3 P48549 7/20 0.39
▸ CYP11B1 P15538 3/20 0.37
▸ CYP11B2 P19099 3/20 0.37
▸ CYP17A1 P05093 2/20 0.37
▸ CYP19A1 P11511 2/20 0.37
▸ KDM4E B2RXH2 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ HPGD P15428 2/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HDAC3 O15379 1/20 0.34
▸ HDAC4 P56524 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34
▸ HDAC7 Q8WUI4 1/20 0.34
▸ HDAC2 Q92769 1/20 0.34
▸ HDAC10 Q969S8 1/20 0.34
▸ HDAC11 Q96DB2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21591555 0.86 KCNA5 (0.40) KCNA5KCNJ5KCNJ3KDM4EMEN1
SCHEMBL21592283 0.84 CYP11B1 (0.41) CYP11B1CYP11B2CYP17A1CYP19A1KDM4E
SCHEMBL21592245 0.79 KCNA5 (0.38) KCNA5KCNJ5KCNJ3HDAC3HDAC4
SCHEMBL21591526 0.78 PDE3B (0.39) KCNA5KCNJ5KCNJ3KDM4EMEN1
SCHEMBL21591463 0.78 CYP11B1 (0.54) KCNA5KCNJ5KCNJ3CYP11B1CYP11B2
SCHEMBL21591506 0.78 HDAC3 (0.40) KCNA5KCNJ5KCNJ3CYP11B1CYP11B2
SCHEMBL21591564 0.75 GPR119 (0.37) KCNA5KCNJ5KCNJ3KDM4EMEN1
SCHEMBL21591432 0.71 KCNA5 (0.42) KCNA5KCNJ5KCNJ3CYP11B1CYP11B2
SCHEMBL21591440 0.70 CYP11B1 (0.60) CYP11B1CYP11B2CYP17A1CYP19A1ALDH1A1
SCHEMBL21591512 0.70 ALDH1A1 (0.43) KDM4EMEN1KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 — — US disclosed
WO-2019238786-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2019-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) STING1, IRF3, CGAS KCNA5 2592/4885KCNJ5 1509/4885KCNJ3 1776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback